Fidelity Investments
IMRX icon

Fidelity Investments’s Immuneering IMRX Stock Holding History

Fidelity Investments’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.4M Buy
9,704,610
+6,672
+0.1% +$33.7K ﹤0.01% 1532
2026
Q1 		$51.1M Buy
9,697,938
+12,443
+0.1% +$63.8K ﹤0.01% 1434
2025
Q4 		$63.7M Buy
9,685,495
+898,443
+10% +$5.77M ﹤0.01% 1342
2025
Q3 		$61.5M Buy
8,787,052
+8,566,052
+3,876% +$44.5M ﹤0.01% 1365
2025
Q2 		$745K Buy
+221,000
New +$379K ﹤0.01% 2825
2024
Q3 		– Sell
-6,743
Closed -$8.63K – 5611
2024
Q2 		$8.63K Sell
6,743
-226,455
-97% -$372K ﹤0.01% 4386
2024
Q1 		$674K Sell
233,198
-256,249
-52% -$1.44M ﹤0.01% 2628
2023
Q4 		$3.6M Sell
489,447
-122,721
-20% -$818K ﹤0.01% 2156
2023
Q3 		$4.7M Sell
612,168
-46,276
-7% -$425K ﹤0.01% 2063
2023
Q2 		$6.68M Buy
658,444
+255,923
+64% +$2.46M ﹤0.01% 1983
2023
Q1 		$3.91M Buy
402,521
+249,458
+163% +$1.42M ﹤0.01% 2169
2022
Q4 		$742K Sell
153,063
-69,951
-31% -$620K ﹤0.01% 2614
2022
Q3 		$3.19M Sell
223,014
-140
-0.1% -$1.11K ﹤0.01% 2295
2022
Q2 		$1.21M Buy
223,154
+9,632
+5% +$51.4K ﹤0.01% 2628
2022
Q1 		$1.38M Buy
213,522
+131,818
+161% +$1.27M ﹤0.01% 2701
2021
Q4 		$1.32M Sell
81,704
-168,296
-67% -$4.1M ﹤0.01% 2637
2021
Q3 		$6.64M Buy
+250,000
New +$6.72M ﹤0.01% 2280

Other funds holding IMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Fidelity Investments's IMRX Position: Q2 2026 in Review

Fidelity Investments increased its Immuneering (IMRX) stake by 0.07% in Q2 2026, buying an estimated $33.7K and bringing the position to 9,704,610 shares worth $48.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1532.

Fidelity Investments first reported a position in IMRX in Q3 2021 and has held it in 17 quarters since. The position peaked at $63.7M in Q4 2025. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Fidelity Investments held 9,704,610 shares of Immuneering worth $48.4M as of Q2 2026.
  • Fidelity Investments bought 6,672 Immuneering shares in Q2 2026, an estimated $33.7K.
  • Immuneering made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1532 holding.
  • Fidelity Investments first reported a position in Immuneering in Q3 2021 and has held it in 17 quarters since.
  • Fidelity Investments's Immuneering position peaked at $63.7M in Q4 2025.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.